Phase II study of everolimus for recurrent or progressive pediatric ependymoma

BACKGROUND: Preclinical studies have suggested that mTOR pathway signaling may be a potential therapeutic target for childhood ependymoma. METHODS: A phase II clinical trial (ClinicalTrials.gov identifier: NCT02155920) of single-agent everolimus was performed to test the hypothesis that mTOR pathway...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowers, Daniel C, Rajaram, Veena, Karajannis, Matthias A, Gardner, Sharon L, Su, Jack Meng-Fen, Baxter, Patricia, Partap, Sonia, Klesse, Laura J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025810/
https://www.ncbi.nlm.nih.gov/pubmed/36950217
http://dx.doi.org/10.1093/noajnl/vdad011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025810/
https://www.ncbi.nlm.nih.gov/pubmed/36950217
http://dx.doi.org/10.1093/noajnl/vdad011

Ejemplares similares